Pharmaceutical Manufacturing Equipment Market Size, Share & Industry Analysis, By Equipment (Mixing & Blending, Milling, Dryer & Granulators, Extrusion, Filling & Compression, Inspection & Sterilization, and Packaging), By Manufacturing Type (Continuous and Batch), By End User (Large Scale Pharma, CDMO, CMO, and CRO), and Regional Forecast, 2025 – 2032

The global pharmaceutical manufacturing equipment market size was valued at USD 22.36 billion in 2024. The market is projected to grow from USD 23.67 billion in 2025 to USD 38.82 billion by 2032, exhibiting a CAGR of 7.3% during the forecast period.

The global market is experiencing robust growth due to increasing demand for medicines, advancements in production technologies, and stringent regulatory compliance. The market operates in a highly competitive environment where efficiency, compliance, and innovation play key roles. With the rise of precision medicine and bio-pharmaceuticals, manufacturers are highly investing in high-tech solutions to enhance production efficiency and regulatory adherence. Geopolitical factors, trade dynamics, and evolving Environmental, Social, and Governance (ESG) policies significantly impact market expansion.

The COVID-19 pandemic accelerated the demand for vaccines and therapeutics, highlighting the resilience in the market for modern medicines. However, continuous innovation and research capabilities have extended market growth potential, infusing billions of investments in the pharmaceutical manufacturing equipment industry. This interplay of factors underscores the market’s dynamic characteristics, where adaptability, technological prowess, and strategic investments are key to success, which is expected to navigate through these challenges and opportunities.

Impact of IoT and Automation

Regulatory Compliance and Need for High-Speed Manufacturing Drive Automation Demand 

The integration of IoT and automation significantly improved efficiency, quality control, and regulatory compliance. COVID-19 has accelerated the digital transformation and increased demand for high-speed manufacturing equipment to meet vaccine and therapeutic production needs. Furthermore, IoT enables real-time monitoring and predictive analytics, which enhances operational efficiency. Automation improves product quality and reduces labor costs, enhancing flexible manufacturing capabilities and driving investments in advanced, adaptable equipment solutions that can swiftly respond to market demands for critical therapeutics and vaccines.

• For instance, in October 2024, Korber and AspenTech announced a partnership to accelerate the digital transformation of pharmaceutical companies by using PAS-X MES and AspenTech Inmation. The solution is designed for clients seeking seamless shopfloor integration with sophisticated data management. The partnership helps deliver enhanced operational efficiency and smarter decision-making. 

Pharmaceutical Manufacturing Equipment Market Trends

Rapid Adoption of SUT and Focus on Advance Technology Shaping Market Trends

Key trends shaping the market include the rapid adoption of continuous manufacturing to reduce production time and costs. Furthermore, Single Use Technologies (SUT), which reduce contamination risk and lower operational costs, are shaping market trends. Anti-counterfeiting technologies, such as advanced sterilization and track & trace solutions, are gaining prominence. Furthermore, there is a heightened focus on equipment that facilitates continuous manufacturing processes, aligning with the need for more efficient production methods. All these advancements and customer needs are fueling market growth.

• For instance, in June 2024, GEA Group, a pioneer in pharma processing solutions, introduced perfusion separators in the continuous manufacturing segment. It is the first single-use disc centrifuge for perfusion designed for high-intensity continuous cell separation.

MARKET DYNAMICS

Market Drivers

Stringent Regulations and Rising Promotion of API Manufacturing to Drive Market Growth

Increased adoption of pharmaceutical manufacturing equipment is propelled by diverse key drivers, including the escalating demand for generic drugs and biologics, which necessitates specialized high-capacity equipment. Increasing demand for API drug manufacturing, continuous advancements in automation, process efficiency, and industry 4.0 adoption are accelerating investment in high-performance equipment. Regulatory compliance, including FDA and EMA guidelines, requires the use of the art machinery for precision and validation. Additionally, the growing reliance on contract manufacturing and outsourcing to low-cost regions supports equipment sales. This is bolstering the pharmaceutical manufacturing equipment market growth.

• For instance, in September 2024, API Innovation Center (APIIC) received USD 14 million as strategic funding to minimize dependency and lead the development and production of three critical active pharmaceutical ingredients (API) used in the treatment of Asthma, diabetes, and anxiety disorders.

Market Restraints

High Capital Investment and Supply Chain Disruptions are Raising Challenges for The Market Growth

High initial capital investment poses a major challenge for small and mid-sized pharmaceutical players. Stringent regulations increase operational complexities, leading to longer equipment validation cycles and higher compliance costs. Also, supply chain disruptions due to geopolitical instability and high tariffs on exports impact businesses in the short term. Additionally, reluctance among traditional manufacturers to transition toward automated and digitalized processes slows down adoption. Despite the growth prospects, the market faces significant restraints, notably due to the exorbitant costs associated with purchasing and maintaining sophisticated pharmaceutical manufacturing equipment, which can be prohibitive for emerging small players.

Market Opportunities

Demand for Sustainable Green Technology Extending Potential Growth in Emerging Markets

The market presents several opportunities for growth, particularly in the development of sustainable green technology tailored for highly advanced cell and gene therapy technology. The increasing focus on sustainability within the pharmaceutical sector opens avenues for eco-friendly equipment solutions. Furthermore, expanding into emerging markets, where there is a growing demand for pharmaceuticals but a shortage of advanced manufacturing capabilities, offers significant potential for equipment suppliers. Thus, sustainability initiatives push for eco-friendly solutions, and opening the door for energy-efficient and waste-reducing equipment will expand the market size during the forecast period.

• For instance, in July 2024, GEA Group introduced pharmaceutical freeze-drying solutions, LYOAIR cooling systems with natural refrigerants. The system comprises highly efficient compressors with an air-circulating system with a carbon dioxide booster, significantly reducing energy consumption.

SEGMENTATION ANALYSIS

By Equipment

Need for Effective Formulation Bolsters the Demand for Dryer and Granulator Equipment 

The equipment segment is divided into mixing & blending, milling, dryer & granulators, extrusion, filling & compression, inspection & sterilization, and packaging.

The dryer and granulator equipment segment is exhibiting robust growth. It acquires the largest market share, owing to the increasing demand for equipment in advanced formulation and medicines production, to increase the effectiveness of the medicine.

The mixing and blending equipment segment is witnessing the highest CAGR due to the creation and development of miniaturized yet effective medicines for exports and the global pharma healthcare industry.

Filling & compression and inspection & sterilization segments are witnessing moderate growth due to increasing API production outsourcing driven by regulatory compliance and anti-counterfeiting measures.

The pharmaceutical packaging, milling, and extraction segments are exhibiting steady growth owing to stringent quality control regulations and growing biological drug production.

By Manufacturing Type

Increasing Demand for Continuous Drug Production Fosters Segment Growth

By manufacturing type, the market segmentation is categorized into continuous and batch.

The continuous manufacturing segment is witnessing the highest growth and share owing to its rapid adoption of technology post-pandemic and easy integration of the technology into the existing automated systems. Also, heavy investment in biopharmaceutical manufacturing facilities and research on mutations in modern disease medicines has shaken the demand for manufacturing technologies.

Batch processing still holds a significant share of the market, driven by efficiency and regulatory support.

By End User

To know how our report can help streamline your business, Speak to Analyst

High Outsourcing of Development and Manufacturing Activities Propel CDMO Segment Growth

By end user, the market segmentation is categorized into large-scale pharma, CDMO, CMO, and CRO.

Across end users, the CDMO segment is witnessing robust growth, acquiring the highest market share owing to the heavy outsourcing of development and manufacturing activities. Also, cost efficiency in the process supports segment growth in the long term.

Large-scale pharma is showcasing moderate growth due to heavy investment in technologically advanced research and formulation equipment.

CMO and CRO equipment are exhibiting steady growth due to a rise in demand for small-scale and regional pharmaceuticals and research laboratories involved in the cosmetics and skin care pharmaceutical segment.

PHARMACEUTICAL MANUFACTURING EQUIPMENT MARKET REGIONAL OUTLOOK

By region, the market is segmented into North America, Europe, Asia Pacific, South America, and the Middle East & Africa.

Asia Pacific

To get more information on the regional analysis of this market, Request a Free sample

Asia Pacific dominates the global market, owing to its strong manufacturing capabilities and rising investments by big manufacturers in the region due to the availability of abundant resources. Also, prominent countries such as China’s technological advancements and cost-effective manufacturing provide an advantage in delivering sustainable yet less costly equipment and medicine solutions to customers. Furthermore, countries such as India, Japan, South Korea, and other Asian countries are growing rapidly as the continuous mutation of new diseases and the need for reliable pharma capacities drive product growth.

Request a Free sample to learn more about this report.

China is estimated to gain the highest market share, supporting its progressive growth due to increasing investment in modern science and pharmaceutical research, and minimizing dependencies on other countries for generic medicines.

To know how our report can help streamline your business, Speak to Analyst

North America

North America is witnessing robust growth driven by the strong presence of major pharmaceutical hubs and a strong focus on innovative manufacturing technologies. North America's strong government policies and investment in new technologies are helping foreign generic drug manufacturers to support this growth.

South America

South America is witnessing consolidated growth owing to its minimal investment and research capabilities in modern medicine manufacturing. Also, the need for upgraded manufacturing infrastructure and easy medicine import are possible causes of this moderate growth.

Europe

Europe is witnessing steady growth driven by the region's emphasis on regulatory compliance and integration of modern Industry 4.0 practices into manufacturing. Also, countries such as Germany, the U.K., and Italy are the biggest markets for product manufacturing as manufacturers prioritize R&D innovations to attain a lead in emerging markets and expand market share.

Middle East & Africa

The Middle East & Africa is showcasing moderate growth due to increasing healthcare infrastructure and demand for medicine, extending pharmaceutical manufacturing capabilities in the long term.

COMPETITIVE LANDSCAPE

KEY INDUSTRY PLAYERS

Tailored Product and Competition-Specific Innovation Extend Manufacturer's Potential

Pharmaceutical manufacturing equipment competition is characterized by a mix of global conglomerates and specialized players focusing on tailored product upgrades and competition-centric innovation through R&D investments. Also, emphasis on collaborations and partnerships with contract manufacturers and pharmaceutical giants to enhance equipment efficiency, automation, and operational performance extended manufacturers' potential growth and expanded pharmaceutical manufacturing equipment market share progressively in the long term.

• For instance, in March 2024, GEA Group, a pioneer in pharmaceutical manufacturing solutions, announced a partnership with HOVIONE and launched ConsSigma CDC flex continuous tableting technology and a lab-scale R&D facility in Portugal.

List of Key Pharmaceutical Manufacturing Equipment Companies Profiled

• GEA Group AG (Germany)


• Syntegon Technology GmbH (Germany)


• Sartorius AG (Germany)


• ACG (India)


• I.M.A. Industria Macchine Automatiche S.p.A.  (Italy)


• Glatt GmbH (Germany)


• Romaco Group (Germany)


• Fette Compacting (Germany)


• Paul Mueller (U.S.)


• SED Pharma (China)


• Marchesini Group S.p.A (Italy)


• Shimadzu Corporation (Japan)


• Becton, Dickinson, and Company (U.S.)


• Thermo Fisher Scientific (U.S.)


• PerkinElmer, Inc. (U.S.)


• Merck KGaA (Germany)


• Agilent Technologies, Inc. (U.S.)


• Korber AG (Germany)


• Shanghai Pharmaceutical Machinery Co. Ltd. (China)


• Robert Bosch GmbH (Germany)

KEY INDUSTRY DEVELOPMENTS

• August 2024: Korber, an international technology group, partnered with Lisure, a specialist in downstream processing solutions, to simplify the integration of Werum PAS-X MES (Manufacturing Execution System) with Lisure's advanced equipment. The goal is to advance automation and informatization in several biopharmaceutical fields. 


• June 2024: Pharmatec, a subsidiary of Syntegon, announced the launch of its new modular BioProcessing Platform (MBP). The MBP is a highly flexible, fully integrated, and automated solution for biological drug substances. The platform can be configured with microbial and mammalian cell culture applications.  


• June 2024: Syntegon, a prominent pharmaceutical process solution provider, launched a new patented development at Achema. The new patented Settle Plate Changer (SPC)for automated viable monitoring in aseptic filling technology will significantly reduce downtime and achieve machine availability noticeably upto 300 hours.


• May 2024: GEA, a global pharmaceutical solution provider, expanded its portfolio of pharmaceutical spray dryers with the launch of GEA ASEPTICSD. The systems are specially designed for pharmaceutical spray drying of antibiotics, vaccines, hormones, and allergens, as well as monoclonal antibodies, powder for parental infusions, blood products, and other versatile solutions.


• March 2024: SBM Essential Line, a subsidiary of Syntegon, launched a new series of sterilizers. The technology features vacuum steam, steam air-mixture, or combined sterilization to sterilize porous and solid equipment as well as liquid in containers such as vials, cartridges, and pens.

REPORT COVERAGE

The report provides a detailed analysis of the market and focuses on key aspects such as leading companies, product/service types, and leading applications of the product. Besides, the report offers insights into the market trends competitive landscape, and highlights key industry developments. In addition to the factors above, the report encompasses several factors that contributed to the growth and impacting the global pharmaceutical manufacturing equipment report.

To gain extensive insights into the market, Request for Customization

REPORT SCOPE & SEGMENTATION